Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

GALVANO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.630
EU - Europa 1.466
AS - Asia 619
AF - Africa 28
SA - Sud America 21
OC - Oceania 10
Totale 7.774
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.618
IT - Italia 665
SG - Singapore 282
CN - Cina 220
DE - Germania 217
GB - Regno Unito 127
FI - Finlandia 96
IE - Irlanda 82
SE - Svezia 59
RU - Federazione Russa 42
RO - Romania 40
BE - Belgio 34
IN - India 29
UA - Ucraina 24
FR - Francia 21
CI - Costa d'Avorio 14
IR - Iran 14
TR - Turchia 14
BR - Brasile 12
ES - Italia 12
NL - Olanda 11
AU - Australia 10
CA - Canada 10
EG - Egitto 10
HK - Hong Kong 10
JP - Giappone 10
AT - Austria 7
KR - Corea 5
MY - Malesia 5
TW - Taiwan 5
CH - Svizzera 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
BG - Bulgaria 3
CL - Cile 3
EE - Estonia 3
GR - Grecia 3
PE - Perù 3
VN - Vietnam 3
AL - Albania 2
BD - Bangladesh 2
CZ - Repubblica Ceca 2
GH - Ghana 2
IL - Israele 2
LK - Sri Lanka 2
LT - Lituania 2
MK - Macedonia 2
MX - Messico 2
PK - Pakistan 2
PL - Polonia 2
PT - Portogallo 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
KW - Kuwait 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
PH - Filippine 1
RS - Serbia 1
Totale 7.774
Salva come PNG Salva come JPEG
Città #
Fairfield 983
Ashburn 527
Chandler 502
Houston 434
Seattle 406
Woodbridge 406
Wilmington 345
Cambridge 336
Ann Arbor 262
Singapore 231
Palermo 208
Medford 102
Des Moines 89
Altamura 78
Dublin 78
New York 70
Princeton 66
Lawrence 61
Ludwigshafen am Rhein 55
San Diego 55
Santa Clara 53
Nanjing 44
Bremen 31
Brussels 31
Dearborn 30
Rome 30
Kitzingen 28
Beijing 27
Helsinki 27
Boardman 25
London 24
Milan 21
Falls Church 19
Redwood City 17
Shenyang 17
Kumar 16
Munich 16
Abidjan 14
Hebei 14
Nanchang 14
Volla 14
Chicago 13
San Paolo di Civitate 12
Berlin 11
Kilburn 11
Phoenix 11
Tulsa 11
Izmir 10
Jinan 10
Los Angeles 10
Milazzo 10
Pune 10
Tehran 10
Lappeenranta 9
Mascalucia 9
Ningbo 9
Saint Petersburg 9
Tappahannock 9
Changsha 8
Dallas 8
Frankfurt am Main 8
Norwalk 8
Orange 8
Tianjin 8
Aversa 7
Cairo 7
Washington 7
Jiaxing 6
Lucera 6
Melbourne 6
Zhengzhou 6
Central 5
Columbus 5
Edinburgh 5
Hilliard 5
Jacksonville 5
Kuala Lumpur 5
Springfield 5
Toronto 5
Turin 5
Verona 5
Cagliari 4
Council Bluffs 4
Guangzhou 4
Hanover 4
Islington 4
New Albany 4
Rimini 4
Riyadh 4
Shanghai 4
Tokyo 4
Agrigento 3
Amsterdam 3
Bologna 3
Caserta 3
Detroit 3
Genoa 3
Hangzhou 3
Lima 3
Madrid 3
Totale 6.190
Salva come PNG Salva come JPEG
Nome #
Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors 218
Dietary restriction: could it be considered as speed bump on tumor progression road? 212
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 201
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 199
Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin 191
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 190
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 188
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 185
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 172
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 170
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 169
Nintedanib in NSCLC: Evidence to date and place in therapy 163
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 162
Monoclonal antibodies in gastrointestinal cancers 161
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 159
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 158
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 154
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 152
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 152
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 141
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 139
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 139
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 139
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 136
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 134
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 126
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 124
Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials 118
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 117
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 117
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 111
Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer 110
Ramucirumab and its use in gastric cancer treatment 106
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer 106
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 102
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 101
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 99
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 94
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 92
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 91
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy 90
2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 88
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 86
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups 86
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 84
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 83
Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer 79
The use of same in chemotherapy-induced liver injury 77
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 76
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer 73
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 71
null 69
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results 68
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety 67
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 66
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 65
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 62
Indications for locoregional tumor therapies: CRC liver metastases 58
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 57
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 53
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 51
Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers 50
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 50
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 46
The treatment of medication-related osteonecrosis of the jaw (Mronj): A systematic review with a pooled analysis of only surgery versus combined protocols 46
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 44
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 44
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 43
Second medical opinion in oncological setting 40
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses 40
Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. 39
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 38
Molecular tumor board 33
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 31
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 31
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 30
Current clinically validated applications of liquid biopsy 30
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 29
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 27
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 26
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 25
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare 24
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors 23
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 23
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 23
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 22
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study 20
PROTACs: The Future of Leukemia Therapeutics 20
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis 19
Liquid biopsy and immunotherapy: is all that glitter gold? 18
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 15
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 15
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 15
Early detection screening: myth or reality? 13
Network approach in liquidomics landscape 13
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 12
Future perspectives 11
Liquid biopsy: a right tool in a right context? 11
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 10
Anti-vibration Knob for the Motorcycle, Customizable on the Basis of the Driver’s Ergonomics 8
Totale 8.364
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.214 0 0 0 0 180 245 163 135 148 136 159 48
2020/20211.393 90 49 151 69 137 89 137 114 115 214 145 83
2021/20221.177 119 209 74 39 63 60 59 67 100 140 91 156
2022/20231.448 148 279 32 186 122 225 85 129 116 20 78 28
2023/2024889 29 100 75 77 60 134 117 80 30 31 14 142
2024/2025690 74 181 174 189 72 0 0 0 0 0 0 0
Totale 8.373